Point of Care Technologies for Nutrition, Infection, and Cancer for Global Health (PORTENT)
Point of Care Technologies for Nutrition, Infection, and Cancer for Global Health (PORTENT)
批准号:
10714506
负责人:
David Carl Erickson
金额:
$160.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-13 至 2028-07-31
关键词:
AddressAfricaAnemiaAreaAsiaBiological SciencesBusinessesCOVID-19 pandemicCapitalCervical Cancer ScreeningClinicalCommunicable DiseasesConsensusDevelopmentDevice or Instrument DevelopmentDevicesDiagnosticDiagnostic testsDirect CostsDisparateEcologyEcuadorEducational workshopElementsEngineeringEntrepreneurshipEventFundingGenerationsHIVHealth PersonnelHealthcare SystemsHumanIncubatorsIndiaIndustrializationInfectionInfrastructureInstitutionInternationalIronKnowledgeLeadershipLettersLow incomeMalariaMalignant NeoplasmsMarketingMindModelingNeeds AssessmentNetwork-basedNew York CityNongovernmental OrganizationsNorth AmericaPatientsPersonsPoint of Care TechnologyPopulationPopulation HeterogeneityPositioning AttributePrimary CarePrimary Health CareQualifyingRegulatory AffairsReportingRotationSexually Transmitted DiseasesSiteSouth AmericaSystemTechnologyTestingTherapeuticTrainingTranslationsTravelUgandaUnited StatesUnited States National Institutes of HealthUniversitiesValidationVeteransclinical research sitecollegecommercializationdiagnostic technologiesearly screeningexperienceglobal healthhealth care disparityinterestlow and middle-income countriesmarginalizationmarginalized populationmultiplex detectionnext generationnutritionpoint of carepoint-of-care diagnosticsprogramsresearch and developmentscreeningstatisticstechnology developmenttechnology validationtraining opportunity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1.0 Overall Abstract
We propose the establishment of PORTENT – “Point-of-Care Technologies for Nutrition, Infection and Cancer
for Global Health” centered at Cornell University in partnership with Columbia and McGill Universities.
The recent Lancet Diagnostic Commission report states that the “diagnostic gap is most severe at the level of primary
health care, in which only about 19% of populations in low-income and lower-middle-income countries have
access to the simplest of diagnostic tests … People who are poor, marginalized, young, or less educated have the
least access to diagnostics.” Developing PoC devices for these populations is challenging. The needs are unique,
the users have disparate qualifications, the path to commercialization is different, the settings have variable
infrastructure, the regulatory agencies have distinctive requirements, and the stakeholders are diverse. The
PORTENT Center is unique as it (1) focuses on primary health care globally; (2) addresses the needs of the
most vulnerable in the US and internationally; and (3) enables a broad range of diagnostic technologies to be
validated on a global scale while simultaneously developing expertise and building capacity internationally
to have the most impact even beyond the center. The center builds on our decades of international experience in
validation, deployment, and commercialization of POC systems and incorporates clinical validation and satellite
technology sites across four continents enabling testing on diverse populations and with a unique set of users.
Our approach is fundamentally enabled by 5 key differentiable elements: (1) A rigorous approach to Needs
Assessment through the establishment of an annual Global PoC Needs Assessment Consensus developed by a
Needs Assessment Advisory Board; (2) The ability to validate PoC technologies on an exceptionally broad range
of established populations and biospecimens in New York City, Ecuador, India, and Uganda; (3) The
establishment of a “Lab-to-Market accelerator for Global Health Point of Care Technologies” to provide
commercialization and tech-to-market support for PORTENT projects; (4) Unique training opportunities and
knowledge transfer workshops for healthcare workers in LMICs on the use of PoC devices and clinical rotations
at our international sites for PoC developers; (5) Access to the team’s network of industrial partners, diagnostics
companies, regulatory experts, venture capital groups, and domestic & international non-governmental
organizations. Illustrative of what we will fund through PORTENT, we describe four “Year 1” projects that (1) enable
early screening of cervical cancer, (2) determination of iron status enabling anemia screening, (3) combined HIV and
multiplexed detection of sexually transmitted diseases, and (4) broader, cheaper, and more accurate malaria testing.
By the end of year 5, PORTENT will: initiate 20 independent PoC technology projects (with 30% from outside
US), engage ~ 15 teams in the Global Health Lab-to-Market accelerator program, train 30 health care workers
from LMICs on use of PoC technologies, and provide >20 clinical rotations for technology developers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Point of Care Technologies for Nutrition, Infection, and Cancer for Global Health (PORTENT)
-
批准号:10714507
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2023
-
负责人:David Carl Erickson
-
依托单位:
Artificial Intelligence and Precision Nutrition Training Program
-
批准号:10752485
-
项目类别:
-
资助金额:$32.44万
-
财政年份:2023
-
负责人:David Carl Erickson
-
依托单位:
Technology Core
-
批准号:10714508
-
项目类别:
-
资助金额:$68.04万
-
财政年份:2023
-
负责人:David Carl Erickson
-
依托单位:
Paper-COVID - Platform for High-throughput SARS-CoV-2 Screening and Contact Tracing
-
批准号:10196383
-
项目类别:
-
资助金额:$43.2万
-
财政年份:2021
-
负责人:David Carl Erickson
-
依托单位:
Development of a Point of Care Multiplexed Diagnostic Platform to Target Anemia and Micronutrient Deficiencies
-
批准号:9542788
-
项目类别:
-
资助金额:$11.39万
-
财政年份:2017
-
负责人:David Carl Erickson
-
依托单位:
Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings using KS-Detect
-
批准号:9334145
-
项目类别:
-
资助金额:$49.9万
-
财政年份:2016
-
负责人:David Carl Erickson
-
依托单位:
FeverPhone: Point of Care Diagnosis of Acute Febrile Illness using a Mobile Device
-
批准号:9008392
-
项目类别:
-
资助金额:$61.16万
-
财政年份:2016
-
负责人:David Carl Erickson
-
依托单位:
Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings using KS-Detect
-
批准号:9031275
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2016
-
负责人:David Carl Erickson
-
依托单位:
Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings using KS-Detect
-
批准号:10018466
-
项目类别:
-
资助金额:$90.68万
-
财政年份:2016
-
负责人:David Carl Erickson
-
依托单位:
FeverPhone: Point of Care Diagnosis of Acute Febrile Illness using a Mobile Device
-
批准号:9301546
-
项目类别:
-
资助金额:$60.03万
-
财政年份:2016
-
负责人:David Carl Erickson
-
依托单位:
A New Approach to Autonomous Point-of-care Tropical Disease Diagnostics Using Sol
-
批准号:8609568
-
项目类别:
-
资助金额:$17.45万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
A New Approach to Autonomous Point-of-care Tropical Disease Diagnostics Using Sol
-
批准号:8443640
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
Single Molecule Optically Resonant NanoTweezers for the study of Intracellular Me
-
批准号:8601119
-
项目类别:
-
资助金额:$28.92万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
KS-Detect: A sample-in, answer-out solution to the Diagnosis of Kaposi's Sarcoma
-
批准号:8780631
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
Single Molecule Optically Resonant NanoTweezers for the study of Intracellular Me
-
批准号:8419345
-
项目类别:
-
资助金额:$27.65万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
KS-Detect: A sample-in, answer-out solution to the Diagnosis of Kaposi's Sarcoma
-
批准号:8636238
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2013
-
负责人:David Carl Erickson
-
依托单位:
Optically Resonant Nanotweezers
-
批准号:8069193
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2010
-
负责人:David Carl Erickson
-
依托单位:
Optically Resonant Nanotweezers
-
批准号:7896973
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2010
-
负责人:David Carl Erickson
-
依托单位:
Nanoscale Optofluidic Pathogen Detection
-
批准号:7847743
-
项目类别:
-
资助金额:$0.78万
-
财政年份:2007
-
负责人:David Carl Erickson
-
依托单位:
Nanoscale Optofluidic Pathogen Detection
-
批准号:7640877
-
项目类别:
-
资助金额:$18.04万
-
财政年份:2007
-
负责人:David Carl Erickson
-
依托单位:
海外基金